Skip to main content
S&P 5007,696.02+1.68%DOW53,299.35+2.92%NASDAQ25,806.01+1.71%BTC$80,353.00+3.61%ETH$2,423.32+5.73%GOLD$4,073.00+3.37%OIL$88.31-8.10%
Smart Investors Daily
SID Premium
TM

NASDAQ · TMDX

TransMedics Group, Inc.

Healthcare · Medical - Devices

$67.34

Up+$6.68 (+9.91%)

Updated Nov 4, 2026, 5:35 PM

SID Score

3.9/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.37B
P/E ratio
47.56
Dividend yield
0.00%
52-week range
$60.11 – $135.28
Volume
707.2K
Avg. volume
933.82K

Price performance · TMDX

TMDX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

TMDX closed at $67.34 after 21 trading sessions, down 16.12% for the selected period.

Last close
$67.34
Period change
-16.12%
Period low
$65.99
Period high
$81.07
Daily close
View OHLC price history
TMDX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$66.90$68.8199$66.36$67.34707.2K
Nov 2, 2026$66.47$68.655$65.84$66.67689.61K
Oct 30, 2026$67.59$67.75$64.64$65.99900.11K
Oct 29, 2026$67.09$69.02$65.52$67.12991.43K
Oct 28, 2026$69.02$69.98$66.68$66.901.18M
Oct 27, 2026$70.53$71.18$69.63$69.73826.61K
Oct 26, 2026$70.01$71.97$69.61$70.63847.93K
Oct 23, 2026$71.42$72.68$69.755$70.74790.1K
Oct 22, 2026$72.34$73.655$70.52$72.06627.7K
Oct 21, 2026$74.47$76.00$72.255$72.40685.95K
Oct 20, 2026$71.65$75.66$67.31$74.751.17M
Oct 19, 2026$71.16$72.81$70.5001$71.60657.14K
Oct 16, 2026$76.52$76.52$70.03$70.781.07M
Oct 15, 2026$74.41$77.34$74.41$76.521.13M
Oct 14, 2026$78.20$78.355$74.84$75.52892.07K
Oct 13, 2026$78.17$80.415$77.86$79.1351.16M
Oct 12, 2026$77.69$78.50$77.14$78.17491.98K
Oct 9, 2026$79.13$81.345$76.86$77.87733.74K
Oct 8, 2026$80.25$80.275$77.50$79.00949.6K
Oct 7, 2026$80.96$83.90$80.56$81.07962.66K
Oct 6, 2026$83.87$84.05$80.08$80.28570.85K

Latest TMDX news

The latest Smart Investors Daily articles mentioning TMDX.

Stock researchCompany · Overview

TMDX research

Overview

Company profile and research snapshot.

Company profile

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$148.00
Implied upside
—
Analysts
20
TMDX recent ratings
DateFirmRatingTarget
Oct 13, 2026Canaccord GenuityBuy—
Oct 7, 2026BarclaysOverweight—
Sep 8, 2026TD CowenBuy—
Aug 5, 2026Piper SandlerOverweight—
Aug 5, 2026UBSNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 30, 2026

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 28, 2026, the Company granted non-qualified stock options to purchase an aggregate of 71,815 shares of its common stock and an aggregate of 47,924 restricted stock units (RSUs) to nine employees. These awards were granted as a material inducement for each employee's entry into

Yahoo · Oct 29, 2026

TransMedics to Present at Upcoming Investor Conferences

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in three upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the Stifel 2026 Healthcare Conference in New York on Tuesday, November 10, 2026, at 10:40 a.m. EST, the Jefferies Global Healthcare Conference in

Yahoo · Oct 22, 2026

TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By